In brief
The rise of GLP‑1 weight‑loss drugs has begun to alter how consumers buy beauty and skin care, L’Oreal said on Thursday. In a call with investors, chief Nicolas Hieronimus noted that the medications’ popularity is impacting product usage, especially in skin‑care lines. L’Oreal is already designing new treatments for the loose skin and sagging that can follow rapid weight loss. Its brands SkinCeuticals and Kiehl's have launched products to complement those changes, while the company has also increased its stake in dermatology firm Galderma. The move signals the beauty industry’s willingness to adapt to a generation of consumers whose health choices shape their skincare habits.
The increase in GLP‑1 weight‑loss drugs is reshaping beauty demand, L’Oreal said on Thursday, as the company noted a measurable impact on skin‑care sales. Boasting a 7.7% rise in revenue for the quarter, the firm said the trend is “a very important phenomenon for us” and that it’s designing products that address specific side‑effects of rapid weight loss. Rapid weight loss can lead to loose skin and sagging, particularly around the face, L’Oreal said, and its SkinCeuticals and Kiehl's brands have launched lines that work alongside GLP‑1 users. Meanwhile, the company has increased its stake in dermatology firm Galderma to 20%, a move that allows it to test anti‑sagging formulations in clinical trials. The shift underscores how medical advances are redefining consumer beauty preferences and is prompting manufacturers to adapt quickly.
